News Release

Suven Life Sciences secures 2 (two) Product Patents for their NCEs through
New mechanism of action H3 Inverse Agonist in USA & New Zealand
HYDERABAD, INDIA (March 16, 2015) - Suven Life Sciences Ltd (Suven) announced today that
they secured patents in USA (8912179) and New Zealand (614567) to one of their New
Chemical Entity (NCE) for CNS therapy through new mechanism of action H3 Inverse agonist
and these patents are valid until 2030 and 2031 respectively. The granted claims of the patent
include the class of selective H3 ligands discovered by Suven and are being developed as
therapeutic agents and are useful in the treatment of cognitive impairment associated with
neurodegenerative disorders.
Histaminargic dysfunction has been strongly associated with the cognitive and behavioral
deficits observed in several CNS disorders. H3 receptor blockade elevates acetylcholine in brain
regions responsible for cognition, thus offer a means for targeting cognitive processes. Novel,
potent, selective, brain penetrant and orally active H 3 receptor inverse agonist for the treatment
of cognitive deficits would offer new line of treatment for this unmet medical need.
With these new patents, Suven has a total of twenty (20) granted patents from USA and twenty
three (23) granted patents from New Zealand. These granted patents are exclusive intellectual
property of Suven and are achieved through the internal discovery research efforts. Products out
of these inventions may be out-licensed at various phases of clinical development like at Phase-I
or Phase-II.
We are very pleased by the grant of these patents to Suven for our pipeline of molecules in
CNS arena that are being developed for cognitive disorders with high unmet medical need with
huge market potential globally says Venkat Jasti, CEO of Suven.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and
commercializing novel pharmaceutical products, which are first in class or best in class CNS
therapies through the use of GPCR targets. The Company has eleven (11) internally-discovered
therapeutic drug candidates currently in pre-clinical stage of development targeting conditions
such as ADHD, dementia, depression, Huntingtons disease, Parkinsons disease and obesity in
addition to Phase 2 ready developmental candidate SUVN-502 for and Phase1 candidate SUVNG3031 for Alzheimers disease and Schizophrenia.

For more information please visit our Web site at http://www.suven.com

Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including
expectations and assumptions, contained in this news release may be forward-looking statements
that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making
these forward-looking statements, it is possible that future circumstances might differ from the
assumptions on which such statements are based. Other important factors which could cause results
to differ materially including outsourcing trends, economic conditions, dependence on collaborative
partnership programs, retention of key personnel, technological advances and continued success in
growth of sales that may make our products/services offerings less competitive; Suven may not
undertake to update any forward-looking statements that may be made from time to time.

Suven Life Sciences Limited

C IN : L 2 41 1 0TG 1 98 9P L C 00 9 71 3
Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor I
Road No.5 I Avenue 7 I Banjara Hills I Hyderabad 500 034 I Telangana I India
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com